Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Chirurgia Italiana|December 1, 1980
[Results of calcitonin therapy of the painful symptoms caused by osteolytic metastases of prostatic carcinoma]P Fabris, G Strada, G Tonazzi, et al.
Journal of Biological Regulators and Homeostatic Agents|January 1, 1995
Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patientsP Lissoni, S Barni, A Ardizzoia, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 12, 2001
Generation of species cross-reactive aptamers using "toggle" SELEXR White, C Rusconi, E Scardino, et al.
European Urology|April 15, 2000
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemiaP Lissoni, M Mandalà, F Rovelli, et al.
Archivio Italiano Di Urologia, Nefrologia, Andrologia : Organo Ufficiale Dell'Associazione Per La Ricerca in Urologia = Urological, Nephrological, and Andrological Sciences|September 1, 1991
[Recurrence of acute lymphoid leukemia in the bladder: a rare cause of bilateral hydronephrosis]R Musci, T Meroni, E Scardino, et al.
La Radiologia Medica|May 15, 2008
Local staging of penile cancer using magnetic resonance imaging with pharmacologically induced penile erectionG Petralia, G Villa, E Scardino, et al.
Anticancer Research|August 21, 2003
Spermatic cord liposarcoma: a report of four casesD V Matei, B Rocco, E Scardino, et al.
Oncology|January 1, 1994
Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinomaP Lissoni, S Barni, A Ardizzoia, et al.
Anticancer Research|April 9, 2005
Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancerB Rocco, M Ferrari, E Scardino, et al.
Tumori|August 31, 1994
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2P Lissoni, S Barni, M Andres, et al.
Pageof 3